M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cancer Patients' Medication Knowledge in the Emergency Center

Completed

Conditions: Advanced Cancer

Interventions: Behavioral: PMKT Questionnaire

First Posted Date: 2006-10-09

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 308

Registration Number: NCT00385476

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Risk Perception Among Quitting Smokers

Conditions: Smoking

Interventions: Drug: Nicotine Replacement Therapy
Behavioral: Questionnaire

First Posted Date: 2006-10-06

Last Posted Date: 2019-05-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 220

Registration Number: NCT00384696

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Endothelial Dysfunction As A Predictor Of Perioperative Outcome

Completed

Conditions: Endothelial Dysfunction

First Posted Date: 2006-10-06

Last Posted Date: 2019-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 90

Registration Number: NCT00384683

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation

Phase 1

Completed

Conditions: Lymphoma
Leukemia
Transplantation, Stem Cell
Lymphoid Malignancies
Disorder Related to Transplantation

Interventions: Drug: GM-CSF
Drug: Rituximab
Biological: NK Cell Infusion

First Posted Date: 2006-10-04

Last Posted Date: 2019-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT00383994

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Leukemia

Interventions: Drug: 5-Azacytidine
Drug: Ara-C
Drug: Valproic Acid (VPA)

First Posted Date: 2006-09-29

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT00382590

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Sargramostim
Drug: Rituximab

First Posted Date: 2006-09-27

Last Posted Date: 2016-01-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00381004

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection

Not Applicable

Withdrawn

Conditions: Cancer

Interventions: Drug: Minocycline-EDTA
Drug: Heparin

First Posted Date: 2006-09-21

Last Posted Date: 2012-02-24

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00378781

The Effects of Thalidomide on Symptom Clusters

Phase 2

Completed

Conditions: Advanced Cancers

Interventions: Drug: Thalidomide
Drug: Placebo

First Posted Date: 2006-09-21

Last Posted Date: 2013-02-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00379353

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)

Phase 2

Completed

Conditions: Leukemia
Lymphoma

Interventions: Drug: Dasatinib (BMS-354825)

First Posted Date: 2006-08-15

Last Posted Date: 2023-12-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 17

Registration Number: NCT00364286

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Revlimid

First Posted Date: 2006-08-07

Last Posted Date: 2013-08-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT00360672

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy